Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet. This is ...

The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...

A clinical trial has found that low-dose interleukin-2 is safe and may significantly extend survival in people with motor ...

A clinical trial has found that low-dose interleukin-2 is both safe and effective for use on people with motor neuron disease ...

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet.

Results of the landmark MIROCALS clinical trial, published in The Lancet, show a low-dose interleukin-2 (IL2LD) is safe, ...

Results of the landmark MIROCALS clinical trial, involving researchers from the University of Sheffield, have revealed new ...

Eric Brunner, from Philadelphia in the US, was running up to three miles a day at the onset of his symptoms in 2020. Months ...

A substantial number of drugs found to alleviate symptoms of motor neuron diseases (MNDs) in animal models have failed in clinical trials. While the reasons for this are not clear, modeling with ...

A high-carbohydrate diet may help people with SMA, as they have metabolic alterations that lead to increased fat burning, per ...

Amyotrophic lateral sclerosis (ALS) – known as Lou Gehrig’s Disease based on the iconic 1930s New York Yankee baseball player ...

Fasciculations are a hallmark symptom of diseases that affect the lower motor neurons, like ALS. Other lower motor neuron diseases that may cause fasciculations include post-polio syndrome, spinal ...